Lexicon Pharmaceuticals, Inc.
LXRX
$-0.04
Change (1 day)
$3.73
Year High
$0.76
Year Low
Categories
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc. (LXRX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 1.01 M | 83.6 M | 136.32 M | 229.43 M | 176.55 M |
| 2022 | 28 K | 8.95 M | 77.18 M | 194.3 M | 140.87 M |
| 2021 | 14 K | -61,786,000 | 23.31 M | 136.91 M | 88.92 M |
| 2020 | 395 K | -113,453,000 | 47.42 M | 203.79 M | 157.72 M |
| 2019 | 56.53 M | 210.17 M | 300.61 M | 417.72 M | 337.75 M |